INSTRUCTIONS - PROFESSORS: Please print and review this form. Complete or correct the sections, as applicable, from "Supervisor's Name" to "Ethics, safety, and training". Please sign and date near the bottom ("Supervisor's signature").
INSTRUCTIONS - STUDENTS: You may receive this form by email, or you may download it after it has been posted here. Either way, print and review this form. Complete or correct the sections, from "Student's Name" to "Student's Level", and sign ("Student signature"). Ask your supervisor to sign her/his section near the bottom. Take it to the department* corresponding to the course number in Section A; this may or may not be your own department. (* EXCEPTIONS: For NSCI 396 and COGS 396, please bring it to the Interdisciplinary Programs Adviser in Dawson Hall.) Do not register for a '396' course on Minerva until you receive departmental permission. Have a discussion with your supervisor about time/work expectations, keeping in mind that this is a 3-credit course (roughly, 10 hours per week for 12 weeks). Remember that a '396' course is an elective.
INSTRUCTIONS - DEPARTMENTS: After the unit chair/director/designate approves (or not) this project, please notify student. If approved, please give student permission to register on Minerva, and send a copy of this form (with signatures) to the Office for Undergraduate Research in Science (either fax, or internal mail to Dawson Hall 408-A, or PDF scan + email).
QUESTIONS OR FEEDBACK? Contact the Office for Undergraduate Research in Science.
Supervisor's Name: Chantal Autexier + Lawrence Panasci
Supervisor's Email: chantal [dot] autexier [at] mcgill [dot] ca
Supervisor's department: Anatomy and Cell Biology
Course number: ANAT 396 (Anatomy and Cell Biology)
Term: Fall 2013-2014
Project start date: Tuesday, September 3, 2013
Project end date: Tuesday, December 3, 2013
Project title: Dasatinib conjugates in CLL therapy- mechanism of action
Project description (50-100 words suggested):
This project will be co-supervised by Dr. Lawrence Panasci and Dr. Chantal Autexier
B-cell chronic lymphocytic leukemia (CLL) is characterized by actively dividing Blymphocytes in the lymph nodes and bone marrow as well as the accumulation of quiescent lymphocytes in the peripheral blood of affected patients. During treatment, the enzyme-mediated repair of DNA damage can induce resistance to chemotherapeutic drugs. Even if combinations of chemotherapy with immunotherapy have shown higher response rates and longer duration of responses, they can be associated with poor tolerability characterized by deterioration of immune functions leading to infections. Thus, there is an urgent need to find curative treatments in chronic lymphocytic leukemia. Dr. Panasci’s laboratory has previously demonstrated that ZRF-4, a combimolecule incorporating imatinib (c-abl inhibitor) plus a chlorambucil-like alkylating agent was more active than the individual components in killing chronic lymphocytic leukemia (CLL) cells obtained directly from patients. Now, Dr. Panasci's lab is investigating a new combi-molecule incorporating a dual Src/c-abl inhibitor (Dasatinib) with a chlorambucil-like alkylating agent. As demonstrated by cytotoxic assay (MTT), these new combi-molecules (AL758 and AL816) are much better than individual components in killing CLL lymphocytes in vitro. The student will perform Western blots and flow cytometry analysis to assess the molecular pathways leading to cell death.
Prerequisite: 1 term completed at McGill + CGPA of 3.0 or higher; or permission of instructor.
Grading scheme (The final report must be worth at least 50% of final grade): 50% final report + 50% evaluation of laboratory performance.
Project status: This project is taken. The professor has no more '396' projects this term.
Ethics, safety, and training: Supervisors are responsible for the ethics and safety compliance of undergraduate students. This project involves: Handling chemicals.